A Single-arm, Dose-escalation Phase I Clinical Study on Evaluating the Tolerability, Pharmacokinetic Characteristics, Safety and Preliminary Efficacy of MT027 in Patients with Recurrent or Progressive High-grade Glioma

The clinical protocol plans to preset three dose groups, namely 1×10⁷ cells per dose, 3×10⁷ cells per dose, and 6×10⁷ cells per dose. The injection will be administered once every three weeks, adopting a "3 + 3" dose escalation design. The dosing interval is based on the pharmacokinetic (PK), safety and preliminary efficacy data of MT027 investigator-initiated trial (IIT) previously conducted at Dushu Lake Hospital of Soochow University. Accordingly, it is recommended to maintain the dosing interval of once every three weeks, with a window period of ±7 days. According to past experience, the dosing cycle should be at least 6 cycles, with each cycle lasting 21 days. If patients still benefit after more than 6 cycles, they can continue to receive the medication until no further benefit is achieved. The number of treatment sessions is approximately 6 to 9 times. However, the specific number of treatment sessions will generally be determined by the investigator based on the patient's disease condition.

开始日期2025-01-01

申办/合作机构

T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd.

NCT06742593

/ Not yet recruiting临床1期

A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3. It is a next-generation, ready-to-use CAR-T product that can be used immediately and promptly for patients to solve the problem of unmet medical needs for a large number of patients who have a demand for CAR-T therapy but cannot receive it due to the common reasons of long production cycle, insufficient production capacity, and incompatibility of patients' T cells with the production conditions. In addition, the expected medical cost of allogeneic CAR-T cells is significantly lower, which can greatly alleviate the economic burden on patients.
MT027 is prepared by expressing a chimeric antigen receptor (CAR) targeting B7H3 on gene-edited T cells through gene modification technology. MT027 products targeting the B7H3 target developed by Moxing Biotech avoid the potential graft-versus-host disease (GvHD) and host anti-graft reaction (HvGR) caused by the interaction between exogenous T cells and the patient's immune system, and have shown good safety and efficacy in recurrent high-grade glioma in the initial phase.

开始日期2025-01-01

申办/合作机构

T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd.

NCT06726564

/ Recruiting临床1期

A Phase 1 Single Arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MT027 in Patients with Pleural Malignant Tumors

This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy..
Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.

开始日期2024-05-15

申办/合作机构

T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd.

[+1]

100 项与 T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd. 相关的专利（医药）

登录后查看更多信息

332

项与 T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd. 相关的新闻（医药）

2025-01-15

·同写意

三启生物：iPSC Pioneer，Crafting Universal Cell Therapy for All | 写意会员

细胞疗法免疫疗法临床申请临床研究

2025-01-14

·同写意

ADC联用PD-L1，宜联生物与阿斯利康达成临床合作 | 会员动态

抗体药物偶联物临床2期临床1期临床3期临床结果

2025-01-13

·同写意

翊曼生物 × 汇松科技：战略合作，共启新程 | 会员动态

疫苗诊断试剂

100 项与 T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年02月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

AMT-253	黑色素瘤更多	临床2期
CD19/BCMA UCAR-T (Suzhou Maoxing Biotechnology) ( BCMA x CD19 )	多发性骨髓瘤更多	临床1期
CLDN18.2 UCAR-T(Suzhou Maximum Bio-tech) ( CLDN18.2 )	胃癌更多	临床1期
MT-027 ( CD276 )	恶性胸膜间皮瘤更多	临床1期
CD19/BCMA CAR-T (Suzhou Maoxing Biotechnology) ( BCMA x CD19 )	多发性骨髓瘤更多	临床1期